Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction

European Journal of Heart Failure

Volumn 16, Issue 9, 2014, Pages 967-976

  Rusinaru, Dan ^a,b   Houpe, David ^b   Szymanski, Catherine ^a   Lévy, Franck ^a   Maréchaux, Sylvestre ^c   Tribouilloy, Christophe ^a,d  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Centre Hospitalier de Saint Quentin   (France)

^c UNIV LILLE   (France)

^d UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Causes of death; Coronary artery disease; Heart failure; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; SUDDEN CARDIAC DEATH; VERY ELDERLY; COMPARATIVE STUDY; COMPLICATION; FORECASTING; FRANCE; HEART FAILURE; HEART STROKE VOLUME; HOSPITALIZATION; INCIDENCE; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TRENDS;

AGED; CAUSE OF DEATH; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; FORECASTING; FRANCE; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE;

EID: 84908223381     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.142     Document Type: Article

References (32)

1. Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, Sadowski Z, Golba KS, Prior DL, Rouleau JL, Bonow RO. Navigating the crossroads of coronary artery disease and heart failure. Circulation 2006;114:1202-1213.
2. Bart BA, Shaw LK, McCants CB Jr, Fortin DF, Lee KL, Califf RM, O'Connor CM. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997;30:1002-1008.
3. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-1084.
4. Purek L, Laule-Kilian K, Christ A, Klima T, Pfisterer ME, Perruchoud AP, Mueller C. Coronary artery disease and outcome in acute congestive heart failure. Heart 2006;92:598-602.
5. Rossi JS, Flaherty JD, Fonarow GC, Nunez E, Gattis Stough W, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, Yancy CW, Young JB, Davidson CJ, Gheorghiade M. Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: A report from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Eur J Heart Fail 2008;10:1215-1223.
6. Gheorghiade M, Flaherty JD, Fonarow GC, Desai RV, Lee R, McGiffin D, Love TE, Aban I, Eichhorn EJ, Bonow RO, Ahmed A. Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure. Int J Cardiol 2011;151:69-75.
7. Mentz RJ, Allen BD, Kwasny MJ, Konstam MA, Udelson JE, Ambrosy AP, Fought AJ, Vaduganathan M, O'Connor CM, Zannad F, Maggioni AP, Swedberg K, Bonow RO, Gheorghiade M. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. Eur J Heart Fail 2013; 15:61-68.
8. Flaherty JD, Bax JJ, DeLuca L, Rossi JS, Davidson CJ, Filippatos G, Liu PP, Konstam MA, Greenberg B, Mehra MR, Breithardt G, Pang PS, Young JB, Fonarow GC, Bonow RO, Gheorghiade M. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol 2009;53:254-263.
9. Shah SJ. Evolving approaches to the management of heart failure with preserved ejection fraction in patients with coronary artery disease. Curr Treat Options Cardiovasc Med 2010;12:58-75.
10. Tribouilloy C, Rusinaru D, Maréchaux S. Heart failure with preserved ejection fraction: looking for new pieces of a complex puzzle. Arch Cardiovasc Dis 2014;107:73-76.
11. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis. Eur Heart J 2012; 33:1750-1757.
12. Choudhury L, Gheorghiade M, Bonow RO. Coronary artery disease in patients with heart failure and preserved systolic function. Am J Cardiol 2002;89:719-722.
13. Judge KW, Pawitan Y, Caldwell J, Gersh BJ, Kennedy JW. Congestive heart failure symptoms in patients with preserved left ventricular systolic function: Analysis of the CASS registry. J Am Coll Cardiol 1991;18:377-382.
14. O'Connor CM, Gattis WA, Shaw L, Cuffe MS, Califf RM. Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol 2000;86:863-867.
15. Chan MM, Lam CS. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 2013;15:604-613.
16. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: A community perspective. Circ Heart Fail 2008;1:91-97.
17. Rickenbacher P, Pfisterer M, Burkard T, Kiowski W, Follath F, Burckhardt D, Schindler R, Brunner-La Rocca HP, TIME-CHF Investigators. Why and how do elderly patients with heart failure die? Insights from the TIME-CHF study. Eur J Heart Fail 2012;14:1218-1229.
18. Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, Slama M, Massy Z. Prognosis of heart failure with preserved ejection fraction: A 5 year prospective population-based study. Eur Heart J 2008;29:339-347.
19. Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology. Eur Heart J 1995;16:741-751.
20. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
21. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010;121:1393-1405.
22. Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JGF, Massie BM, Ryden L, on behalf of the ATLAS study group. Mode of death in heart failure: Findings from the ATLAS trial. Heart 2003;89:42-48.
23. Mozaffarian D, Anker SA, Anand I, Linker DT, Sullivan MD, Cleland JGF, Carson PE, Maggioni AP, Mann DL, Pitt B, Poole-Wilson PA, Levy WC. Prediction of mode of death in heart failure. The Seattle Heart Failure Model. Circulation 2007;116:392-398.
24. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526.
25. Fine JP, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
26. Adams KF Jr, Dunlap SH, Sueta CA, Clarke SW, Patterson JH, Blauwet MB, Jensen LR, Tomasko L, Koch G. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996;28:1781-1788.
27. Mentz RJ, Broderick S, Shaw LK, Fiuzat M, O'Connor CM. Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for cardiovascular disease). J Am Coll Cardiol 2014;63:251-258.
28. Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA. Effect of candesartan on cause-specific mortality in heart failure patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004;110:2180-2183.
29. Adabag S, Smith LG, Anand IS, Berger AK, Luepker RV. Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail 2012;18:749-754.
30. Grigorian-Shamagian L, Otero Raviña F, Abu Assi E, Vidal Perez R, Teijeira-Fernandez E, Varela Roman A, Moreira Sayagues L, Gonzalez-Juanatey JR. Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. Am Heart J 2008;156:1184-1190.
31. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550.
32. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, Ghali JK, Liebson PR. Heart failure with a normal ejection fraction: Is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001;104:779-782.